Skip to Content
Merck
  • Intramuscular diclofenac sodium versus intravenous Baralgin in the treatment of renal colic.

Intramuscular diclofenac sodium versus intravenous Baralgin in the treatment of renal colic.

DICP : the annals of pharmacotherapy (1990-04-01)
J Sanahuja, G Corbera, J Garau, R Plá, M Carmen Carré
ABSTRACT

A comparative, randomized, double-blind study of diclofenac sodium 75 mg im versus Baralgin (a combination drug composed of dipyrone and two spasmolytics) 5 mL iv was performed on 57 patients with renal colic. Both groups were comparable as to age, sex, pain evolution time before treatment, and no treatment for renal colic in the six hours preceding trial drug administration. No significant differences were found between the two groups with respect to the evolution of pain after the first dose or in the frequency of administration of a second dose. Tolerability was good in both groups, but sweating and pain throughout the vein were observed in one patient in the Baralgin group. We concluded that diclofenac sodium constitutes an excellent alternative to pyrazolone analgesics, with the advantages of being monotherapy and having good tolerability, when used as intramuscular injection in ambulatory patients.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Pitofenone hydrochloride, ≥98% (HPLC)